Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
Phase 2 Terminated
3 enrolled 10 charts
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Phase 2 Terminated
1 enrolled 7 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
Phase 2 Terminated
5 enrolled 10 charts
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Phase 2 Terminated
3 enrolled 4 charts
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
Phase 2 Terminated
13 enrolled 5 charts
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase 2 Terminated
342 enrolled 14 charts
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
39 enrolled 10 charts
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
Phase 2 Terminated
30 enrolled 4 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Phase 2 Terminated
3 enrolled 13 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Phase 2 Terminated
9 enrolled 13 charts
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Phase 2 Terminated
50 enrolled 18 charts
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Phase 2 Terminated
24 enrolled 15 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 11 charts
Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer
Phase 2 Terminated
3 enrolled
Cord Blood Transplantation for Patients With Cancer
Phase 2 Terminated
1 enrolled 4 charts
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
Phase 2 Terminated
7 enrolled 10 charts
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
8 enrolled 11 charts
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
Phase 2 Terminated
5 enrolled 4 charts
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Phase 2 Terminated
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
Phase 2 Terminated
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts